The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution*
暂无分享,去创建一个
Eric F. Johnson | C. Stout | J. Yano | G. Schoch | M. Wester | K. Griffin | C. David Stout | Jason K. Yano | Michael R. Wester | Guillaume A. Schoch | Keith J. Griffin | E. F. Johnson | M. R. Wester
[1] G. Wilkinson. Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of pharmacokinetics and biopharmaceutics.
[2] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[3] Eric F. Johnson,et al. Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å Resolution , 2004, Journal of Biological Chemistry.
[4] C David Stout,et al. Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.
[5] James R. Halpert,et al. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[7] C David Stout,et al. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. , 2003, Biochemistry.
[8] C David Stout,et al. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.
[9] M. J. Coon,et al. Kinetic isotope effects implicate two electrophilic oxidants in cytochrome p450-catalyzed hydroxylations. , 2003, Journal of the American Chemical Society.
[10] J. Halpert,et al. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.
[11] Sam-Yong Park,et al. Crystallization and preliminary X-ray diffraction analysis of fatty-acid hydroxylase cytochrome P450BSβ from Bacillus subtilis , 2002 .
[12] C. Wolf,et al. CYP3A4 active site volume modification by mutagenesis of leucine 211. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[13] P. Ortiz de Montellano,et al. Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. , 2002, Biochemistry.
[14] Eric F. Johnson,et al. Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. , 2002, Methods in enzymology.
[15] J. Halpert,et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.
[16] J. Halpert,et al. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. , 2000, The Journal of pharmacology and experimental therapeutics.
[17] M. Sutcliffe,et al. Amino acid 305 determines catalytic center accessibility in CYP3A4. , 2000, Biochemistry.
[18] J Berendzen,et al. The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.
[19] J. Halpert,et al. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. , 2000, Archives of biochemistry and biophysics.
[20] Eric F. Johnson,et al. Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme , 2000, The Journal of Biological Chemistry.
[21] D E McRee,et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.
[22] E. Tanaka,et al. Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.
[23] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[24] T. Richardson,et al. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. , 1998, Biochemistry.
[25] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[26] J. Halpert,et al. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[28] James R. Halpert,et al. Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.
[29] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[30] A. Li,et al. Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.
[31] S. Wrighton,et al. Interactions of peroxyquinols with cytochromes P450 2B1, 3A1, and 3A5: influence of the apoprotein on heterolytic versus homolytic O-O bond cleavage. , 1995, Archives of biochemistry and biophysics.
[32] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[33] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[34] G J Kleywegt,et al. Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.
[35] S. Sligar,et al. A role for Asp-251 in cytochrome P-450cam oxygen activation. , 1994, The Journal of biological chemistry.
[36] E. Johnson,et al. Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. , 1988, The Journal of biological chemistry.
[37] C. Jefcoate,et al. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. , 1978, Methods in enzymology.